Clinical mass spectrometry has ease measuring and distinguishing of separate contributions of molecules such as thyroid hormones and 25-hydroxyl vitamins D2 and D3. This advantage of such a device is expected to drive the growth of the clinical mass spectrometry market. Growing demand for automation in diagnostic techniques such as functional metabolomics, genomics, and proteomics is again supporting the growth of the market. Manufacturers are highly focused on the development and launch of advanced devices to cater to the growing demand for automated diagnostic tools. For instance, in 2017, Thermo Fisher Scientific Inc. launched Scientific Cascadion SM Clinical Analyzer at a EuroMedLab event held in Athens, Greece, to use the clinical analyzers with the selectivity and sensitivity of liquid chromatography-tandem mass spectrometry.
In June 2020, Agilent Technologies have announced the launch of two new mass spectrometry (MS) products: the Agilent 6470B Triple Quadrupole LC/MS (6470 LC/TQ) system, and the Agilent RapidFire 400 system
In June 2017, Thermo Scientific Cascadion launched clinical analyzers with the selectivity and sensitivity of liquid chromatography-tandem mass spectrometry (LC-MS/MS)
In April 2021, bioMérieux, a marketer in the field of in-vitro diagnostics, has announced the CE-marking of VITEK® MS PRIME, the next generation of the VITEK® MS MALDI-TOF1 mass spectrometry system for routine microbial identification in minutes.
North America is projected to dominate the global clinical mass spectrometry market over the forecast period, due to Research and development activities, and increasing governmental support. For instance, the Federation of Analytical Chemistry and Spectrometry Societies, and the American Society for Mass Spectrometry, which was formed in 1969, with over 7,500 scientists working together on advancing the clinical application of mass spectrometry and allied topics in academic, industrial, and governmental fields.
The clinical mass spectrometry (CMS) method involves the analysis of a specific sample by using a sample of the patient's bodily fluids. The sample is broken up into its various components via ultra-filtration, through a process called ionization, and then further broken down through electrodensity. The mass and size of each individual component are then measured. In clinical mass spectrometry, this process is followed by computerized analysis to give a detailed report on the analyte concentration found in the sample. Clinical mass spectroscopy has now become a crucial diagnostic test used in a wide range of fields and has helped save thousands of lives.
